journal
https://read.qxmd.com/read/38922692/critical-peripheral-ischemia-higher-prevalence-in-indian-systemic-lupus-erythematosus-inception-cohort-for-research-inspire
#1
JOURNAL ARTICLE
Vineeta Shobha, Liza Rajasekhar, Sandra Manuel, Nayana V, Ranjan Gupta, Saumya Ranjan Tripathy, Parasar Ghosh, Chengappa Kavadichanda, Ashish J Mathew, Manish Rathi, Avinash Jain, Sumitra Selvam, Amita Aggarwal
INTRODUCTION: There is limited literature on digital ischemia in systemic Lupus erythematosus (SLE). We report the prevalence, associations and outcome of digital infarcts and gangrene from the Indian SLE inception cohort (INSPIRE). METHODS: From the web-based database of INSPIRE, we extracted information for patients with 'Digital Infarct' and 'Digital gangrene' at enrolment into cohort, together considered as critical peripheral ischemia (CPI); all others were controls...
June 26, 2024: Lupus
https://read.qxmd.com/read/38901433/drug-induced-lupus-erythematosus-in-childhood-case-based-review
#2
LETTER
Valerio Maniscalco, Antonella Mollo, Maria Vincenza Mastrolia, Ilaria Maccora, Ilaria Pagnini, Gabriele Simonini, Edoardo Marrani
No abstract text is available yet for this article.
June 20, 2024: Lupus
https://read.qxmd.com/read/38901042/anifrolumab-treatment-improves-patient-reported-quality-of-life-and-decreases-disease-activity-and-corticosteroid-use-in-patients-with-systemic-lupus-erythematosus-a-qualitative-study-in-denmark
#3
JOURNAL ARTICLE
Anne Troldborg, Lauren Remkus, Daniel Eek, Bent Deleuran
Anifrolumab is a new therapeutic approach for individuals with systemic lupus erythematosus (SLE) directed at blocking the type 1 interferon pathway. Despite the expanding body of literature on Anifrolumab, an essential aspect remains absent: the subjective patient experience of treatment effects and implications on patients' health-related quality of life (HRQoL). The present study aimed to fill this void by elucidating the nuanced perspectives of SLE patients receiving Anifrolumab treatment by conducting qualitative in-depth interviews (IDIs)...
June 20, 2024: Lupus
https://read.qxmd.com/read/38885489/associations-between-tca-cycle-plasma-metabolites-and-fatigue-in-black-females-with-systemic-lupus-erythematosus-an-untargeted-metabolomics-pilot-study
#4
JOURNAL ARTICLE
Laura P Kimble, Arezou Khosroshahi, Glenna S Brewster, Sandra B Dunbar, Dylan Ryan, Nicole Carlson, Ron Eldridge, Madelyn Houser, Elizabeth Corwin
OBJECTIVE: In this pilot study, we used untargeted metabolomics to identify biochemical mechanisms or biomarkers potentially underlying SLE-related fatigue. METHODS: Metabolon conducted untargeted metabolomic plasma profiling using ultrahigh performance liquid chromatography/tandem mass spectrometry on plasma samples of 23 Black females with systemic lupus erythematosus (SLE) and 21 no SLE controls. Fatigue phenotypes of general fatigue, physical fatigue, mental fatigue, reduced activity, and reduced motivation were measured with the reliable and valid Multidimensional Fatigue Inventory (MFI)...
June 17, 2024: Lupus
https://read.qxmd.com/read/38860334/belimumab-induced-periungual-pyogenic-granulomas-a-case-report
#5
JOURNAL ARTICLE
Cecilia Beatrice Chighizola, Ilaria Suardi, Achille Marino, Maurizio Gattinara, Stefania Costi, Angelo Cattaneo, Maria Gerosa, Roberto Caporali
Pyogenic granuloma (PG) is a benign vascular neoformation, presenting as a painful red nodule on the skin, mucosa or nail apparatus. It is usually related to local complications such as bleedings and superinfections. The etiology of PG remains still unclear, and several triggers can lead to its formation. In case of multiple lesions, systemic conditions and drugs remain the main causes. Antineoplastic treatments, retinoids, antiretrovirals, hormones and anticonvulsants are frequently implicated in PG formation...
June 11, 2024: Lupus
https://read.qxmd.com/read/38860319/sustained-depression-of-b-cell-counts-in-lupus-nephritis-after-treatment-with-rituximab-and-or-belimumab-is-associated-with-fewer-disease-flares
#6
JOURNAL ARTICLE
Diane Zisa, Jeffrey Zhang-Sun, Paul J Christos, Kyriakos A Kirou
OBJECTIVE: To study the risk of lupus nephritis flare (LNF) or severe lupus flare (SLF) as a function of B cell count kinetics in lupus nephritis (LN) patients after they achieve at least a partial renal response (PRR) with induction treatment that includes rituximab (RTX) and/or belimumab (BLM). METHODS: We performed a retrospective analysis of a cohort of 19 patients with severe LN that received a B cell agent (BCA), RTX and/or BLM, as part of an initial treatment regimen for an LN flare and had subsequent CD19+ B cell measurements in peripheral blood...
June 11, 2024: Lupus
https://read.qxmd.com/read/38853349/the-additional-role-of-anti-nucleosome-antibodies-in-the-prediction-of-renal-damage-in-systemic-lupus-erythematosus-based-on-cstar-xxv
#7
JOURNAL ARTICLE
Yufang Ding, Yangzhong Zhou, Jiuliang Zhao, Chanyuan Wu, Shangzhu Zhang, Nan Jiang, Junyan Qian, Li Zhang, Jing Li, Dong Xu, Xiaomei Leng, Qian Wang, Xinping Tian, Mengtao Li, Xiaofeng Zeng
OBJECTIVES: The predominant determinant of an unfavorable prognosis among Systemic Lupus Erythematosus (SLE) patients resides in the irreversible organ damage. This prospective cohort study aimed to identify the additional value of anti-nucleosome antibodies on organ damage accumulation in SLE patients. METHODS: Based on the Chinese SLE Treatment and Research group (CSTAR) registry, demographic characteristics, autoantibodies profiles, and clinical manifestations were collected at baseline...
June 9, 2024: Lupus
https://read.qxmd.com/read/38844422/impact-of-intimate-partner-violence-on-quality-of-life-and-disease-activity-in-women-with-systemic-lupus-erythematosus
#8
JOURNAL ARTICLE
Emmanuel Campos-Tinajero, Maria Fernanda Ortiz-Nuño, Diana Paola Flores-Gutierrez, Jorge Antonio Esquivel-Valerio, Gisela Garcia-Arellano, Jesus Alberto Cardenas-de la Garza, Estefania Aguilar-Rivera, Dionicio A Galarza-Delgado, Griselda Serna-Peña
OBJECTIVE: Stress and trauma are psychosocial factors with an impact on the course of systemic lupus erythematosus (SLE). The influence of violence on SLE has not been entirely explored, even though women (including patients with rheumatic diseases) are a vulnerable population to any form of violence. This study aims to assess the prevalence and impact of intimate partner violence (IPV) on health-related quality of life in women with SLE. METHODS: An observational, cross-sectional, and analytical study was conducted at a rheumatology clinic of a university hospital from September 2022 and September 2023...
June 6, 2024: Lupus
https://read.qxmd.com/read/38830236/evaluation-of-health-literacy-and-its-association-with-medication-adherence-and-quality-of-life-in-childhood-onset-systemic-lupus-erythematosus
#9
JOURNAL ARTICLE
McKenzie Vater, Alaina Davis, Sarah Jaser
OBJECTIVE: Little is known about health literacy in childhood-onset systemic lupus erythematosus (cSLE) and how health literacy relates to medication adherence and psychosocial outcomes in this high-risk population. The objective of this study was to evaluate health literacy in adolescents and young adults with cSLE and its association with medication adherence and quality of life. METHODS: Youth 10-24 years with cSLE ( n = 48) completed the Brief Healthy Literacy Screen (BHLS) and the Newest Vital Sign (NVS) to assess health literacy...
June 3, 2024: Lupus
https://read.qxmd.com/read/38809681/growth-arrest-specific-protein-6-as-a-marker-of-nephritis-in-systemic-sclerosis-and-juvenile-systemic-lupus-erythematosus-patients
#10
JOURNAL ARTICLE
Alshymaa A Ahmed, Dina Said, May M Sami
Background: Renal impairments commonly occur as a complication of autoimmune connective tissue diseases (CTDs). Therefore, early nephritis prediction is vital for patient outcomes. Growth Arrest-Specific Protein 6 (GAS6) was found to be upregulated in many types of inflammatory renal disease, including diabetic nephropathy. Aim: To evaluate GAS6 as a predictor of renal impairment in adults with systemic sclerosis (SSc) and children with systemic lupus Erythematosus (SLE). Methods: The study included 60 patients with SSc and 40 children with SLE...
May 29, 2024: Lupus
https://read.qxmd.com/read/38782407/association-of-c-677-c-t-rs1801133-and-c-1298-a-c-rs1801131-mthfr-genetic-variants-with-cardiometabolic-and-disease-risk-in-systemic-lupus-erythematosus-patients-a-cross-sectional-study
#11
JOURNAL ARTICLE
Karen Pesqueda-Cendejas, Isela Parra-Rojas, Bertha Campos-López, Paulina E Mora-García, Adolfo I Ruiz-Ballesteros, Melissa Rivera-Escoto, Sergio Cerpa-Cruz, Ulises De la Cruz-Mosso
Systemic lupus erythematosus (SLE) patients present a high prevalence of cardiometabolic risk, associated with worse clinical manifestations and mortality. Folate, an essential micronutrient that participates in vital immune cellular functions, could positively affect the cardiometabolic and disease risk in SLE, through the methylenetetrahydrofolate reductase (MTHFR) enzyme, which participates in the folate metabolism, where single nucleotide variants (SNVs) have been described as a potential genetic risk factor for SLE...
May 23, 2024: Lupus
https://read.qxmd.com/read/38774953/evaluation-of-depressive-and-anxiety-symptoms-in-childhood-onset-systemic-lupus-erythematosus-frequency-course-and-associated-risk-factors
#12
JOURNAL ARTICLE
Kate M Neufeld, Paris Moaf, Michelle Quilter, Ashley N Danguecan, Julie Couture, Daniela Dominguez, Olivia Hendrikx, Lawrence Ng, Reva Schachter, Daphne D Korczak, Deborah M Levy, Linda Hiraki, Andrea M Knight
BACKGROUND: Depressive and anxiety symptoms are common in childhood-onset systemic lupus erythematosus (cSLE), yet their etiology and course remain unclear. We investigated the frequency of depressive and anxiety symptoms longitudinally in youth with cSLE, and associated socio-demographic and disease factors. METHODS: Participants 8-18 years with cSLE completed baseline measures [demographic questionnaire, Center for Epidemiologic Studies Depression Scale for Children (CES-DC), Screen for Childhood Anxiety Related Disorders (SCARED), and psychiatric interview] and follow-up measures (CES-DC and SCARED) > 6 months later...
May 22, 2024: Lupus
https://read.qxmd.com/read/38770549/dr-eng-meng-tan-august-26-1926-march-9-2024-la-jolla-california
#13
JOURNAL ARTICLE
Philip K Tan, Edward Kl Chan, Marvin J Fritzler
No abstract text is available yet for this article.
May 21, 2024: Lupus
https://read.qxmd.com/read/38769901/mortality-in-patients-with-systemic-lupus-erythematosus-a-meta-analysis-of-overall-and-cause-specific-effects
#14
JOURNAL ARTICLE
Young Ho Lee, Gwan Gyu Song
OBJECTIVES: Our objective was to assess the overall and cause-specific standardized mortality ratios (SMRs) among patients diagnosed with systemic lupus erythematosus (SLE). METHODS: An exhaustive systematic review was undertaken, encompassing studies that scrutinized SMRs, both overall and for specific causes, in patients diagnosed with SLE compared to the general populace. The databases of PUBMED, EMBASE, and Cochrane were meticulously searched to collate relevant literature...
May 21, 2024: Lupus
https://read.qxmd.com/read/38745410/uncommon-toxic-epidermal-necrolysis-like-presentation-of-cutaneous-lupus-erythematosus-a-series-of-6-cases
#15
JOURNAL ARTICLE
Varun Rajagopal, Anupama Bains, Karthick Kannan, Abhishek Bhardwaj, Poonam Elhence
TEN like Lupus erythematosus is an uncommon life-threatening variant of Lupus erythematosus. It is usually associated with flares of systemic lupus erythematosus and also because of widespread skin erosions, it can cause acute skin failure. It is often confused with drug induced TEN, however the management of both the diseases is different and hence correct diagnosis becomes crucial. In this study we aimed to assess the clinical characteristics and outcome of TEN like LE in the Indian population. All patients satisfying ACR/EULAR 2019 criteria for SLE and clinically diagnosed with TEN like LE were retrospectively reviewed...
May 14, 2024: Lupus
https://read.qxmd.com/read/38739464/detection-of-genetic-mutations-underlying-early-onset-systemic-lupus-erythematosus
#16
JOURNAL ARTICLE
Seher Sener, Erdal Sag, Xu Han, Yelda Bilginer, Qing Zhou, Seza Ozen
OBJECTIVE: We aimed to investigate the presence of monogenic causes of systemic lupus erythematosus (SLE) in our early-onset SLE patients. METHODS: Fifteen pediatric SLE cases who had early disease onset (≤6 years) were enrolled in this study. All patients fulfilled the Systemic Lupus International Collaborating Clinics (SLICC) criteria. Genomic DNA was used for whole exome sequencing (WES). Pathogenic variants were confirmed by Sanger sequencing. RESULTS: The median age at diagnosis of 15 early-onset SLE patients included in the study was 4 (2-6) years (F/M = 12/3)...
May 13, 2024: Lupus
https://read.qxmd.com/read/38722195/headache-in-systemic-lupus-erythematosus-the-luna-registry-cross-sectional-study
#17
JOURNAL ARTICLE
Ryota Takamatsu, Yasuhiro Shimojima, Dai Kishida, Takanori Ichikawa, Ken-Ichi Ueno, Yoshia Miyawaki, Nobuyuki Yajima, Ken-Ei Sada, Kunihiro Ichinose, Ryusuke Yoshimi, Shigeru Ohno, Hiroshi Kajiyama, Michio Fujiwara, Shuzo Sato, Takashi Kida, Yusuke Matsuo, Keisuke Nishimura, Toshihide Toriyama, Yoshiki Sekijima
OBJECTIVES: This study investigated the clinically relevant factors for headaches in patients with systemic lupus erythematosus (SLE) using a registry from a Japanese multicenter cohort. METHODS: This cross-sectional study analysed the clinical information of patients with SLE who experienced headache episodes using the Migraine Disability Assessment (MIDAS) questionnaire. Significant findings in the comparisons between patients with headache (HA patients) and those without headache (non-HA patients) and in the comparisons depending on the grades of headache-induced disability in daily life based on the MIDAS scores were evaluated...
May 9, 2024: Lupus
https://read.qxmd.com/read/38709772/relationship-of-serum-and-dietary-vitamin-d-with-high-cardiometabolic-risk-in-mexican-systemic-lupus-erythematosus-patients-a-cross-sectional-study
#18
JOURNAL ARTICLE
Adolfo I Ruiz-Ballesteros, Alejandra Betancourt-Núñez, Mónica R Meza-Meza, Melissa Rivera-Escoto, Paulina E Mora-García, Karen Pesqueda-Cendejas, Barbara Vizmanos, Isela Parra-Rojas, Bertha Campos-López, Margarita Montoya-Buelna, Sergio Cerpa-Cruz, Ulises De la Cruz-Mosso
Objetive: Serum and dietary vitamin D could influence clinical disease activity and cardiometabolic outcomes in systemic lupus erythematosus (SLE). This study aimed to assess the relationship of serum and dietary vitamin D with cardiometabolic risk in Mexican SLE patients and healthy subjects (HS). Methods: 224 SLE patients and 201 HS were included in this cross-sectional study. Serum calcidiol was measured using a competitive enzyme-linked immunosorbent assay (ELISA). Vitamin D dietary intake was assessed by collecting three 24h food records...
May 6, 2024: Lupus
https://read.qxmd.com/read/38670796/risk-factors-for-hospitalization-in-mexican-patients-with-systemic-lupus-erythematosus
#19
JOURNAL ARTICLE
Iveth Eunice García-Cañas, Enrique Cuevas-Orta, David Alejandro Herrera-Van Oostdam, Carlos Abud-Mendoza, Lunpos Group
INTRODUCTION: Systemic lupus erythematosus (SLE) is an autoimmune disease that often requires hospitalization. Most hospitalizations are due to infections and/or disease activity, for which several risk factors have been described in non-Mestizo patients. OBJECTIVE: To identify risk factors for hospitalization in patients with systemic lupus erythematosus (SLE). METHODS: This was an observational case-control study of patients with SLE in San Luis Potosí, Mexico, evaluated from January 2019 to October 2020...
April 26, 2024: Lupus
https://read.qxmd.com/read/38664230/addition-of-constitutional-symptoms-to-the-sledai-2k-improves-overall-disease-activity-assessment-a-pilot-study
#20
JOURNAL ARTICLE
Erik W Anderson, Marissa Sansone, Bhakti Shah, Myriam Kline, Giovanni Franchin, Cynthia Aranow, Meggan Mackay
OBJECTIVE: Constitutional symptoms (fatigue, lymphadenopathy, and weight loss) are not included in the SLE disease activity index-2000 (SLEDAI-2K). In this pilot study, we assessed the concurrent and construct validity of a revised SLEDAI-2K (SLED-R) that included these symptoms with the original SLEDAI-2K (SLED-O), using the physician global assessment of disease activity (PGA) as the reference. METHODS: Our revised SLED-R substituted the SLED-O's fever descriptor with a constitutional descriptor that included fever, fatigue, lymphadenopathy, and/or weight loss...
April 25, 2024: Lupus
journal
journal
20193
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.